Andrew Leavitt, MD

Hematologist

Dr. Andrew Leavitt is director of UCSF's program for noncancerous blood disorders as well as co-director of the UCSF Hemophilia Treatment Center. He cares for patients with nonmalignant blood diseases, including bleeding disorders (such as hemophilia and von Willebrand disease), platelet function disorders, disorders of insufficient platelets, venous thromboembolic disorders (which involve blood clots), neutropenia (reduced numbers of the white blood cells called neutrophils) and anemia.

Leavitt is medical director of UCSF's laboratory for blood and marrow transplant research. He is internationally known for his studies of the development of megakaryocytes, large cells in the bone marrow that divide to produce blood platelets. His research also focuses on improving treatment and outcomes for patients with venous thromboembolic diseases.

Leavitt obtained his medical degree at Harvard Medical School. He completed a residency in internal medicine and served as chief resident at the University of Michigan. At UCSF, he completed a fellowship in hematology and oncology, followed by a fellowship in transfusion medicine. He joined the UCSF faculty in 1992.

Leavitt has served on the editorial boards of Blood and the Journal of Clinical Investigation. He currently serves on the editorial board of the Journal of Clinical and Translational Science.

More about Andrew Leavitt

Education

Harvard School of Medicine 1984

Residencies

University of Michigan Hospital, Internal Medicine 1988

Fellowships

UCSF Medical Center, Hematology/Oncology 1991
UCSF Medical Center, Transfusion Medicine 1992

Selected Research and Publications

  1. Leavitt AD. A Small Step Closer But Not Yet There: Oral Anti-Xa Agents and the Treatment of Cancer-Associated Venous Thromboembolism. J Natl Compr Canc Netw. 2018 May; 16(5):572-574.
  2. Lee EJ, Dykas DJ, Leavitt AD, Camire RM, Ebberink E, García de Frutos P, Gnanasambandan K, Gu SX, Huntington JA, Lentz SR, Mertens K, Parish CR, Rezaie AR, Sayeski PP, Cromwell C, Bar N, Halene S, Neparidze N, Parker TL, Burns AJ, Dumont A, Yao X, Chaar CIO, Connors JM, Bale AE, Lee AI. Whole-exome sequencing in evaluation of patients with venous thromboembolism. Blood Adv. 2017 Jul 11; 1(16):1224-1237.
  3. Lefrançais E, Ortiz-Muñoz G, Caudrillier A, Mallavia B, Liu F, Sayah DM, Thornton EE, Headley MB, David T, Coughlin SR, Krummel MF, Leavitt AD, Passegué E, Looney MR. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. Nature. 2017 04 06; 544(7648):105-109.
  4. Sakurai K, Zhao S, Takatoh J, Rodriguez E, Lu J, Leavitt AD, Fu M, Han BX, Wang F. Capturing and Manipulating Activated Neuronal Ensembles with CANE Delineates a Hypothalamic Social-Fear Circuit. Neuron. 2016 Nov 23; 92(4):739-753.
  5. Buckner TW, Leavitt AD, Ragni M, Kempton CL, Eyster ME, Cuker A, Lentz SR, Ducore J, Leissinger C, Wang M, Key NS. Prospective, multicenter study of postoperative deep-vein thrombosis in patients with haemophilia undergoing major orthopaedic surgery. Thromb Haemost. 2016 07 04; 116(1):42-9.
  6. Pietras EM, Reynaud D, Kang YA, Carlin D, Calero-Nieto FJ, Leavitt AD, Stuart JM, Göttgens B, Passegué E. Functionally Distinct Subsets of Lineage-Biased Multipotent Progenitors Control Blood Production in Normal and Regenerative Conditions. Cell Stem Cell. 2015 Jul 02; 17(1):35-46.
  7. Low E, Tessler R, Hauer KE, Leavitt AD, Miller B, Maa J. The Surgical Clerkship and Medical Student Performance in a Standardized Patient Case of Acute Cholecystitis. J Surg Educ. 2015 Sep-Oct; 72(5):1045-51.
  8. Roubinian NH, Leavitt AD. Shedding a little light on posttransfusion purpura. Transfusion. 2015 Feb; 55(2):232-4.
  9. Wilson JG, Liu KD, Zhuo H, Caballero L, McMillan M, Fang X, Cosgrove K, Vojnik R, Calfee CS, Lee JW, Rogers AJ, Levitt J, Wiener-Kronish J, Bajwa EK, Leavitt A, McKenna D, Thompson BT, Matthay MA. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med. 2015 Jan; 3(1):24-32.
  10. Liu KD, Wilson JG, Zhuo H, Caballero L, McMillan ML, Fang X, Cosgrove K, Calfee CS, Lee JW, Kangelaris KN, Gotts JE, Rogers AJ, Levitt JE, Wiener-Kronish JP, Delucchi KL, Leavitt AD, McKenna DH, Thompson BT, Matthay MA. Design and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome. Ann Intensive Care. 2014; 4:22.
  11. Kamata T, Dankort D, Kang J, Giblett S, Pritchard CA, McMahon M, Leavitt AD. Hematopoietic expression of oncogenic BRAF promotes aberrant growth of monocyte-lineage cells resistant to PLX4720. Mol Cancer Res. 2013 Dec; 11(12):1530-41.
  12. Jacquot C, Moayeri M, Kim B, Shugarts S, Lynch KL, Leavitt AD. Prolonged ceftriaxone-induced immune thrombocytopenia due to impaired drug clearance: a case report. Transfusion. 2013 Nov; 53(11):2715-21.
  13. Choi YS, Patena W, Leavitt AD, McManus MT. Widespread RNA 3'-end oligouridylation in mammals. RNA. 2012 Mar; 18(3):394-401.
  14. Leavitt AD, Hamlett I. Homologous recombination in human embryonic stem cells: a tool for advancing cell therapy and understanding and treating human disease. Clin Transl Sci. 2011 Aug; 4(4):298-305.
  15. Leavitt AD. A vote for scientists as politicians. Science. 2011 Feb 25; 331(6020):1010.
  16. Leavitt AD. Are there more tricks in the bag for treating thrombocytopenia? J Clin Invest. 2010 Nov; 120(11):3807-10.
  17. King FW, Ritner C, Liszewski W, Kwan HC, Pedersen A, Leavitt AD, Bernstein HS. Subpopulations of human embryonic stem cells with distinct tissue-specific fates can be selected from pluripotent cultures. Stem Cells Dev. 2009 Dec; 18(10):1441-50.
  18. Alian A, Griner SL, Chiang V, Tsiang M, Jones G, Birkus G, Geleziunas R, Leavitt AD, Stroud RM. Catalytically-active complex of HIV-1 integrase with a viral DNA substrate binds anti-integrase drugs. Proc Natl Acad Sci U S A. 2009 May 19; 106(20):8192-7.
  19. Nicholas CR, Gaur M, Wang S, Pera RA, Leavitt AD. A method for single-cell sorting and expansion of genetically modified human embryonic stem cells. Stem Cells Dev. 2007 Feb; 16(1):109-17.
  20. Kamata T, Kang J, Lee TH, Wojnowski L, Pritchard CA, Leavitt AD. A critical function for B-Raf at multiple stages of myelopoiesis. Blood. 2005 Aug 01; 106(3):833-40.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.